5 AI Companies Using Epidemiology to Fight Coronavirus

Apr 1, 2020 | Blog | 0 comments

Daniel Gigante

In the AI vs COVID-19 battle there are three major areas where breakthroughs are needed, coming and have arrived: diagnosis, treatment and epidemiology. In this post, we focus on five companies who are using epidemiology to aid researchers and the general public in the fight against COVID-19.

1. Qventus – Qventus is an AI-based software platform that optimizes patient flow across the hospital including emergency departments and inpatient units. With respect to COVID-19, Qventus helps in two ways (1) with a free epidemiological model that predicts COVID cases and capacity of key resources at a local (metropolitan) level on a daily basis; and (2) with AI-based interventions for COVID command centers, which provide leaders with situational awareness across the health system and allow them to optimize usage of critical resources such as Med-Surg beds, ICU beds, negative airflow isolation rooms, and ventilators.

2. AgileMD – AgileMD offers a mobile-optimized platform that delivers clinical manuals, protocols, and policies for point-of-care use. With respect to COVID-19, they’ve successfully deployed clinical pathways for inpatient, ambulatory, and the emergency room workflows within the electronic health record. They’re currently offering their software and services free to any compatible hospitals facing COVID-19.

3. Akido Labs – Akido Labs partners with large healthcare organizations to help them harness and leverage the power of their data. They’re providing emergency services coordination, disease surveillance, stress monitoring, and testing coordination as part of their COVID-19 response program.

4. Traces – Traces utilizes artificial intelligence to analyze video using 2000 different attributes of a person, except their face. The team feels their software can be used to trace who came into close proximity with those diagnosed. They’re currently offering their product free of charge, to existing customers.

5. Biobot – Biobot develops technology to transform sewers into public health observatories. Their plan is to analyze sewage samples from more than 100 cities across the country with the goal of figuring out how many people have contracted the coronavirus and how quickly it’s spreading.

This list is far from exhaustive, but we hope it provides some insight into the amazing work some companies are doing in the fight against coronavirus.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest